biotech
Thrombosis Drug Dabigatran on Phase III Clincial Trials
Filed in archive Drugs, Vaccines and Therapeutics by ruth on February 14, 2007
Thrombosis Drug Dabigatran on Phase III Clincial Trials
An international study of 2,000 adult patients with deep vein thrombosis and pulmonary embolism will test if dabigatran, a new oral blood thinner, could be a feasible alternative to warfarin (Coumadin™). Doctors leading the study say that unlike warfarin, dabigatran, which is manufactured by German biopharmaceutical firm Boehringer Ingelheim, does not appear to be easily affected by the patient's diet or other medications.

Should this new drug prove to be effective, it could help cut the estimated 600,000 cases of pulmonary embolisms that occur annually in the United States, as well as deep vein thrombosis, which is twice as common.

More details of the study from the Medical College of Georgia.

[Image: Thrombosis Interest Group of Canada]



Permalink: Thrombosis Drug Dabigatran on Phase III Clincial Trials
Tags: thrombosis  warfarin  DVT  biotech  phase  thrombosis+drug  phase+clincial  clincial+trials 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/53579
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Thrombosis Drug Dabigatran on Phase III Clincial Trials:

  • Currently 8.83/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 8.83 out of 6 vote(s) cast.
 
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!